BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23217953)

  • 1. Bendamustine-induced "flagellate dermatitis".
    Mahmoud BH; Eide MJ
    Dermatol Online J; 2012 Nov; 18(11):12. PubMed ID: 23217953
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Toxicodermia by bendamustine: development of a desensization protocol].
    Sangrador Pelluz C; Luis Hidalgo MM; Martínez García M; Pérez-Serrano Lainosa MD; Soler Company E
    Farm Hosp; 2013; 37(5):421-3. PubMed ID: 24128107
    [No Abstract]   [Full Text] [Related]  

  • 3. Short communication: bendamustine-related hemolytic anemia in chronic lymphocytic leukemia.
    Goldschmidt N; Gural A; Ben-Yehuda D; Gatt ME
    Cancer Chemother Pharmacol; 2013 Sep; 72(3):709-13. PubMed ID: 23907444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy-related acute myeloid leukemia in a patient with chronic lymphocytic leukemia treated with rituximab-bendamustine.
    García-Muñoz R; García DK; Roldán-Galiacho V; Merchante-Andreu M; Campeny-Najara A; Rabasa P
    Ann Hematol; 2014 Apr; 93(4):699-702. PubMed ID: 23907409
    [No Abstract]   [Full Text] [Related]  

  • 5. Preliminary experience with the use of bendamustine: a peculiar skin rash as the commonest side effect.
    Malipatil B; Ganesan P; Sundersingh S; Sagar TG
    Hematol Oncol Stem Cell Ther; 2011; 4(4):157-60. PubMed ID: 22198186
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain.
    Sanchez-Gonzalez B; Peñalver FJ; Medina A; Guillén H; Calleja M; Gironella M; Arranz R; Sebastian E; de Oña R; Cánovas A; de la Fuente I; Grande C; Sancho JM; Perez R; Domingo E; Lopez-Lorenzo JL; Prieto E; Panizo C; Gorosquieta A; Perez I; Cervera JM; Marin M; Mencha C; Ramila E; Salar A
    Leuk Res; 2012 Jun; 36(6):709-14. PubMed ID: 22154023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe cutaneous interface drug eruption associated with bendamustine.
    Alamdari HS; Pinter-Brown L; Cassarino DS; Chiu MW
    Dermatol Online J; 2010 Jul; 16(7):1. PubMed ID: 20673529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial.
    Knauf WU; Lissitchkov T; Aldaoud A; Liberati AM; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Merkle K; Montillo M
    Br J Haematol; 2012 Oct; 159(1):67-77. PubMed ID: 22861163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.
    Cuneo A; Marchetti M; Barosi G; Billio A; Brugiatelli M; Ciolli S; Laurenti L; Mauro FR; Molica S; Montillo M; Zinzani P; Tura S
    Leuk Res; 2014 Nov; 38(11):1269-77. PubMed ID: 25063524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bleomycin-induced flagellate dermatitis.
    Vuerstaek JD; Frank J; Poblete-Gutiérrez P
    Int J Dermatol; 2007 Nov; 46 Suppl 3():3-5. PubMed ID: 17973877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bendamustine.
    Keating MJ; Bach C; Yasothan U; Kirkpatrick P
    Nat Rev Drug Discov; 2008 Jun; 7(6):473-4. PubMed ID: 18511926
    [No Abstract]   [Full Text] [Related]  

  • 12. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
    Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
    Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bendamustine: a new look at an old drug.
    Kalaycio M
    Cancer; 2009 Feb; 115(3):473-9. PubMed ID: 19117340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.
    Woods B; Hawkins N; Dunlop W; O'Toole A; Bramham-Jones S
    Value Health; 2012; 15(5):759-70. PubMed ID: 22867787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ujjani C; Cheson BD
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1353-65. PubMed ID: 20836669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bendamustine's emerging role in the management of lymphoid malignancies.
    Rummel MJ; Gregory SA
    Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bendamustine therapy in chronic lymphocytic leukemia.
    Masiello D; Tulpule A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bendamustine-induced immune hemolytic anemia in a chronic lymphocytic leukemia patient: A case report and review of the literature.
    Haddad H; Mohammad F; Dai Q
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):162-4. PubMed ID: 24785506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generalized purpuric drug exanthem with hemorrhagic plaques following bendamustine chemotherapy in a patient with B-prolymphocytic leukemia.
    Gavini A; Telang GH; Olszewski AJ
    Int J Hematol; 2012 Mar; 95(3):311-4. PubMed ID: 22290027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.